当前或既往乳腺癌及其他恶性肿瘤患者的COVID-19疫苗相关腋窝及颈部淋巴结病:MRI、CT和PET-CT横断面影像表现
本文报告肿瘤患者接种COVID-19疫苗后在乳腺MRI、CT或PET-CT上出现腋窝或颈部淋巴结病的影像表现,指出疫苗相关淋巴结病可与淋巴结转移无法区分,并讨论处理策略及减少假阳性的考虑,同时报告疫苗接种与影像发现淋巴结病之间的时间间隔。
要点
- 疫苗接种可导致I-III级腋窝及颈部淋巴结病,在肿瘤患者中可与淋巴结转移无法区分。
- 本文展示肿瘤患者接种疫苗后乳腺MRI、CT或PET-CT上的腋窝或颈部淋巴结病影像表现。
- 处理策略因临床背景而异,并讨论减少接种疫苗癌症患者假阳性的策略。
核心结论
- 肿瘤患者接种COVID-19疫苗后可在横断面影像上出现腋窝或颈部淋巴结病,与淋巴结转移无法区分,适当处理因临床背景而异。
研究设计与样本
- 本文为影像表现报告,展示当前或既往恶性肿瘤患者接种COVID-19疫苗后在乳腺MRI、CT或PET-CT上见到的腋窝或颈部淋巴结病的影像表现,并报告疫苗接种与影像发现淋巴结病之间的时间间隔。
关键影像表现/征象
- 接种COVID-19疫苗后可出现I-III级腋窝淋巴结病及颈部淋巴结病。
- 在当前或既往恶性肿瘤患者中,疫苗相关淋巴结病可与淋巴结转移无法区分。
临床应用与阅片要点
- 乳腺放射科医生接诊与COVID-19疫苗接种相关的腋窝淋巴结病患者日益增多。
- 疫苗相关淋巴结病的适当处理可能因临床背景而异。
- 文中讨论了处理策略及理由,并考虑减少接种疫苗癌症患者假阳性的策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Breast radiologists are increasingly seeing patients with axillary adenopathy related to COVID-19 vaccination. Vaccination can cause levels I-III axillary as well as cervical lymphadenopathy. Appropriate management of vaccine-related adenopathy may vary depending on clinical context. In patients with current or past history of malignancy, vaccine-related adenopathy can be indistinguishable from nodal metastasis. This article presents imaging findings of oncology patients with adenopathy seen in the axilla or neck on cross-sectional imaging (breast MRI, CT, or PET-CT) after COVID-19 vaccination. Management approach and rationale is discussed, along with consideration on strategies to minimize false positives in vaccinated cancer patients. Time interval between vaccination and adenopathy seen on breast MRI, CT, or PET-CT is also reported.
引用
- Lane DL, Neelapu SS, Xu G, et al. COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT. Korean J Radiol. 2021. PMID: 34719892. doi:10.3348/kjr.2021.0350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。